Aptose to Present New CG-806 Data at the 2018 ASH Annual Meeting
01 nov. 2018 09h26 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Immuron to Receive $2.16M R&D Tax Concession Refund
24 janv. 2018 09h30 HE
|
Immuron Limited
Melbourne, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development...
Actinium Pharmaceuticals Provides Update on Pivotal Phase 3 Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial Continue
27 déc. 2017 09h00 HE
|
Actinium Pharmaceuticals
Actinium expects enhanced awareness of Iomab-B at ASH annual meeting and expanded site activity to enable completion of trial enrollment by end of 2018, in-line with prior forecast NEW YORK, Dec. ...
Actinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual Meeting
12 déc. 2017 07h30 HE
|
Actinium Pharmaceuticals
Higher cell death observed with Actinium-225 labeled daratumumab with up to ten-fold higher potency as compared to naked daratumuambARC of Daratumumab-Actinium-225 labeled with high yield, high...
Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
11 déc. 2017 16h30 HE
|
Aileron Therapeutics, Inc.
Preclinical data show dual inhibition of MDM2 and MDMX restores p53 function Data demonstrate strong anti-cancer effects in models of T-cell lymphomas and acute myeloid leukemia ATLANTA, Dec. 11,...
Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M
11 déc. 2017 16h15 HE
|
Actinium Pharmaceuticals
Analysis of patient data from a large U.S. library revealed that twenty-five percent of Multiple Myeloma patients have CD33 expression on their multiple myeloma cells supporting the rational for...
OHSU and Aptose Present CG’806 Preclinical Data at ASH 59th Annual Meeting
11 déc. 2017 16h04 HE
|
Aptose Biosciences, Inc.
PORTLAND, Ore. and SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- The OHSU Knight Cancer Institute and Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical...
Aptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting
11 déc. 2017 16h04 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical data from research led by The University of...
Actinium Pharmaceuticals Announces Positive Preliminary Results from Phase 2 Trial for Actimab-A Highlighted at 59th American Society of Hematology Annual Meeting
11 déc. 2017 06h30 HE
|
Actinium Pharmaceuticals
69% Overall Response Rate and 98% median reduction in bone marrow blasts reported with Actimab-A given at 2.0 µCi/kg/fraction as a single agent Minimal extramedullary toxicities observed; No evidence...
Rafael Pharmaceuticals to Present New Data Validating Efficacy of CPI-613 in Treating Acute Myeloid Leukemia at the 2017 American Society of Hematology Annual Meeting & Exposition
07 déc. 2017 08h55 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Dec. 07, 2017 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production...